Skip to content
Stock screener

CNTB Connect Biopharma Holdings Ltd stock chart & analysis

Conviction 40HealthcareScan · Thu, Nov 19, 2026

Connect Biopharma Holdings Ltd (CNTB) closed at $0.6203 (-6.75%) on Nov 19, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 33, RS Rating 6, -83.8% from its 52-week high, -78.0% year to date. Sector: Healthcare · Pharmaceutical Preparations.

CNTB$0.6203-6.75%
ResistanceSupportVol 14Insider buy
Loading chart…

Why CNTB moved

From the StockSetups movers recaps that covered CNTB, newest first. A recap states what was known that day.

  • Premarket+84.0%

    The catalyst is clear. Connect Biopharma announced positive preliminary topline data from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD (chronic obstructive pulmonary disease) and Type 2 inflammation.

    Premarket Movers Sept 30, 2026: CNTB, LGHL, VBIO →
Connect Biopharma Holdings LtdPharmaceutical Preparationswww.connectbiopharm.com ↗
Price0.6203
Change-6.75%
Gap-4.51%
Rel volume—
Avg volume597.24K
Avg $ vol445.9K
SMA 200.7352
SMA 500.9339
SMA 2002.07
Price vs 50-33.58%
Price vs 200-70.04%
MA stackbearish
50/200 cross—
Supertrenddown · 0.8113
RSI (14)33
MACD hist0.01
MACD cross—
Stoch %K / %D27 / 24
ADX (14)18
+DI / −DI14 / 26
RSI divergence—
MACD divergenceBullish
ATR %13.27%
ADR %8.99%
52w high3.82
52w low0.5500
From 52w high-83.76%
Above 52w low+12.78%
New 52w highNo
SqueezeOff
Bollinger width42.48%
%B0.13
Donchian pos20.90%
Donchian high0.8863
Donchian low0.5500
AVWAP (52w high)1.47
vs AVWAP high-57.84%
AVWAP (52w low)0.6114
vs AVWAP low+1.46%
OBV trendDown
Chaikin MF (20)-0.09
Today vs 20d—
Avg vol (14d)440.68K
Avg vol (20d)597.24K
Avg $ vol (20d)445.9K
Market cap40M
RS Rating6 / 99
RS 3m (vs SPY)-67.20%
RS 6m (vs SPY)-70.10%
RS line new highNo
Trend template0/8
Technical rank11.3
1 week-6.76%
1 month-22.28%
3 months-73.72%
6 months-73.72%
1 year-75.86%
YTD-78.00%
P/E-0.72
P/B3.32
P/S625.03
P/FCF-0.77
EPS-1.00
Div yield—
ROE-460.22%
ROA-199.78%
Debt/Eq—
Current1.49
EV/EBITDA-0.41
Gross margin—
Net margin—
Rev growth-99.75%
EPS growth-255.00%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value23.5M
Revenue736K
Net income-16.15M
Gross profit—
Free cash flow-51.64M
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out62.96M
Employees64
ListedWed, Sep 3, 2025
Free float56.52M
Float %100.0%
Short interest—
Days to cover—
Short volume79.8%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction40 / 100
Pattern quality—
Tech rank11.3 / 100
Group rank14 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance1.40
Support0.6409
Days since event—
Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

CNTB technical analysis

Trend

CNTB is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 33.6% below the 50-day ($0.9339) and 70.0% below the 200-day ($2.07). ADX(14) at 18 points to a weak trend — more range than direction. It meets 0 of 8 trend-template criteria.

Momentum

RSI(14) is 33, in the bearish half of its range. The MACD histogram is positive. A bullish MACD divergence is in place. Its RS Rating of 6 puts its weighted 12-month performance ahead of about 6% of the US market.

Volume and volatility

It trades about $445,899 a day on average. ATR(14) is $0.0823, 13.3% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.09) shows distribution.

Key levels

The chart pattern's support is $0.6409 and its resistance $1.40. The 52-week range is $0.5500 to $3.82; price is 83.8% below the high and 12.8% above the low. The VWAP anchored at the 52-week high is $1.47, above price.

Performance

CNTB returned -6.8% (1 week), -22.3% (1 month), -73.7% (3 months), -73.7% (6 months), -75.9% (1 year), -78.0% (year to date).

About Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Pharmaceutical Preparations · Listed 2025 · 64 employees

Insider activity

SEC Form 4 transactions in CNTB · open-market 1 buy

InsiderSideShares
Huang James
Director · Ordinary Shares · 2026-05-29
Buy150K

SEC filings

EDGAR filings in CNTB · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.